Published on in Vol 11, No 7 (2022): July
Preprints (earlier versions) of this paper are
available at
https://preprints.jmir.org/preprint/35565, first published
.
Journals
- Sunavala-Dossabhoy G, Petti S. Effect of recombinant human thyroid stimulating hormone on long-term salivary gland dysfunction in thyroid cancer patients treated with radioactive iodine. A systematic review. Oral Oncology 2023;136:106280 View
- Piciu D, Bran S, Moldovan M, Varvara S, Piciu A, Cuc S, Moisescu-Goia C, Barbus E, Mester A, Onisor F. Radioiodine-131 Therapy Used for Differentiated Thyroid Cancer Can Impair Titanium Dental Implants: An In Vitro Analysis. Cancers 2023;15(9):2558 View
- Baudin C, Bressand A, Buffet C, Menegaux F, Soret M, Lê A, Cardon T, Broggio D, Bassinet C, Huet C, Armengol G, Richardson D, Leenhardt L, Bernier M, Lussey-Lepoutre C. Dysfunction of the Salivary and Lacrimal Glands After Radioiodine Therapy for Thyroid Cancer: Results of the START Study After 6-Months of Follow-Up. Thyroid® 2023 View
- Villela R, Correa R. Lacrimal and Salivary Gland Dysfunction Following Radioiodine Therapy for Thyroid Cancer. Clinical Thyroidology® 2023;35(9):384 View
- Legrand A, Bernier M, Bressand A, Buffet C, Mandin C, Menegaux F, Soret M, Broggio D, Bassinet C, Huet C, Leenhardt L, Lussey-Lepoutre C, Baudin C. Health-related quality of life and radioiodine therapy in thyroid cancer patients: a before-and-after study. Quality of Life Research 2024;33(10):2721 View